Table 4 Results of the deterministic sensitivity analysis of posaconazole versus SAT in the prevention of IFI among high-risk neutropenic patients

Probability of IFI; Posaconazole

0.025

Dominant*

Dominant*

0.075

Dominant*

Dominant*

Probability of IFI; SAT

0.075

Dominant*

Dominant*

0.15

Dominant*

Dominant*

Probability of an IFI-related death; Posaconazole

0.2678

Dominant*

Dominant*

0.4464

Dominant*

Dominant*

Probability of an IFI-related death; SAT

0.3636

Dominant*

Dominant*

0.6060

Dominant*

Dominant*

Probability of death from other

0.1185

Dominant*

Dominant*

causes; non IFI-related

0.1975

Dominant*

Dominant*

Relative survival; AML

0.16

Dominant*

Dominant*

0.26

Dominant*

Dominant*

Relative survival; MDS

0.06

Dominant*

Dominant*

0.10

Dominant*

Dominant*

Total treatment cost per day; Posaconazole

77.77

Dominant*

Dominant*

129.61

Dominant*

Dominant*

Total treatment cost per day; Fluconazole

12.70

Dominant*

Dominant*

21.16

Dominant*

Dominant*

Total treatment cost† per day; Itraconazole

16.39

Dominant*

Dominant*

27.31

Dominant*

Dominant*

Discount rate for costs and benefits

0%

Dominant*

Dominant*

5%

Dominant*

Dominant*